echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Letrozole plus Abbesilil for recurrent ER-positive endometrial cancer

    J Clin Oncol: Letrozole plus Abbesilil for recurrent ER-positive endometrial cancer

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Estrogen receptor (ER)-positive endometrial carcinoma (EC) is characterized by PI3K pathway mutations in about 90% of cases and about 80% of cases carrying receptor tyrosine kinase (RTK)/RAS/β-catenin (CTNNB1) pathway variants


    The researchers speculate that the combined application of the aromatase inhibitor letrozole and the CDK4/6 inhibitor abemaciclib may benefit significantly in


    The study is a phase II, two-stage clinical trial designed to evaluate the efficacy and safety



    As of December 3, 2021, a total of 30 patients have received the study treatment; Fifteen (50%) patients had previously received hormone therapy


    The most common treatment-related adverse effects of grade 3 and above are neutropenia (20%) and anemia (17%)


    Exploratory tumor analysis revealed several candidate predictors associated with treatment response mechanisms (CTNNB1, KRAS and CDKN2A mutations, TP53 mutations [associated with no response to treatment]) that require independent validation


    Overall, the findings show that letrozole plus Abbesilil exhibits encouraging sustained therapeutic activity


    Original Source:

    Panagiotis A.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.